BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Custodia A, Aramburu-Núñez M, Correa-Paz C, Posado-Fernández A, Gómez-Larrauri A, Castillo J, Gómez-Muñoz A, Sobrino T, Ouro A. Ceramide Metabolism and Parkinson's Disease-Therapeutic Targets. Biomolecules 2021;11:945. [PMID: 34202192 DOI: 10.3390/biom11070945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gaggini M, Pingitore A, Vassalle C. Plasma Ceramides Pathophysiology, Measurements, Challenges, and Opportunities. Metabolites 2021;11:719. [PMID: 34822377 DOI: 10.3390/metabo11110719] [Reference Citation Analysis]
2 Pantaleo E, Monaco A, Amoroso N, Lombardi A, Bellantuono L, Urso D, Lo Giudice C, Picardi E, Tafuri B, Nigro S, Pesole G, Tangaro S, Logroscino G, Bellotti R. A Machine Learning Approach to Parkinson’s Disease Blood Transcriptomics. Genes 2022;13:727. [DOI: 10.3390/genes13050727] [Reference Citation Analysis]
3 Beger AW, Dudzik B, Woltjer RL, Wood PL. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease. Metabolites 2022;12:187. [DOI: 10.3390/metabo12020187] [Reference Citation Analysis]
4 Robida PA, Chumanevich AP, Gandy AO, Fuseler JW, Nagarkatti P, Nagarkatti M, Oskeritzian CA. Skin Mast Cell-Driven Ceramides Drive Early Apoptosis in Pre-Symptomatic Eczema in Mice. Int J Mol Sci 2021;22:7851. [PMID: 34360617 DOI: 10.3390/ijms22157851] [Reference Citation Analysis]
5 Ma M, Moulton MJ, Lu S, Bellen HJ. 'Fly-ing' from rare to common neurodegenerative disease mechanisms. Trends Genet 2022:S0168-9525(22)00080-4. [PMID: 35484057 DOI: 10.1016/j.tig.2022.03.018] [Reference Citation Analysis]
6 Anghelescu A, Onose G, Popescu C, Băilă M, Stoica S, Postoiu R, Brumă E, Petcu I, Ciobanu V, Munteanu C. Parkinson’s Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment. Biomedicines 2022;10:1000. [DOI: 10.3390/biomedicines10051000] [Reference Citation Analysis]
7 Kurzawa-Akanbi M, Tammireddy S, Fabrik I, Gliaudelytė L, Doherty MK, Heap R, Matečko-Burmann I, Burmann BM, Trost M, Lucocq JM, Gherman AV, Fairfoul G, Singh P, Burté F, Green A, McKeith IG, Härtlova A, Whitfield PD, Morris CM. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathol 2021;142:961-84. [PMID: 34514546 DOI: 10.1007/s00401-021-02367-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Blokhin V, Shupik M, Gutner U, Pavlova E, Lebedev AT, Maloshitskaya O, Bogdanov V, Sokolov S, Alessenko A, Ugrumov M. The Sphingolipid Asset Is Altered in the Nigrostriatal System of Mice Models of Parkinson’s Disease. Biomolecules 2022;12:93. [DOI: 10.3390/biom12010093] [Reference Citation Analysis]
9 Esfandiary A, Finkelstein DI, Voelcker NH, Rudd D. Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery. Cells 2022;11:1353. [DOI: 10.3390/cells11081353] [Reference Citation Analysis]
10 Gomez-Larrauri A, Das Adhikari U, Aramburu-Nuñez M, Custodia A, Ouro A. Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer. Medicina (Kaunas) 2021;57:729. [PMID: 34357010 DOI: 10.3390/medicina57070729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]